Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

92.41USD
26 Jun 2019
Change (% chg)

-- (--)
Prev Close
$92.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,052,572
52-wk High
$98.97
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

BeiGene Regains Global Rights to Investigational Anti-PD-1 Antibody Tislelizumab
Monday, 17 Jun 2019 

June 17 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REGAINS FULL GLOBAL RIGHTS TO ITS INVESTIGATIONAL ANTI-PD-1 ANTIBODY TISLELIZUMAB.BEIGENE LTD - ENTERED INTO A MUTUAL AGREEMENT WITH CELGENE CORPORATION TO TERMINATE PARTIES' GLOBAL COLLABORATION FOR TISLELIZUMAB.BEIGENE LTD - IN CONNECTION WITH TERMINATION, CELGENE HAS AGREED TO PAY $150 MILLION TO BEIGENE.BEIGENE LTD - BEIGENE EXPECTS TISLELIZUMAB TO RECEIVE ITS FIRST REGULATORY APPROVAL LATER THIS YEAR..  Full Article

Celgene And Acceleron Announce FDA Acceptance Of Biologics License Application For Luspatercept
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Celgene Corp ::CELGENE CORPORATION AND ACCELERON PHARMA ANNOUNCE U.S. FDA ACCEPTS LUSPATERCEPT BIOLOGICS LICENSE APPLICATION IN MYELODYSPLASTIC SYNDROMES AND BETA-THALASSEMIA.  Full Article

Celgene Presents Data From A Phase 1/2 Clinical Study Of Iberdomide In Combination With Dexamethasone
Sunday, 2 Jun 2019 

June 2 (Reuters) - Celgene Corp ::CELGENE PRESENTS DATA FROM A PHASE 1/2 CLINICAL STUDY OF IBERDOMIDE IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AT ASCO 2019.CELGENE C- INVESTIGATIONAL TREATMENT DEMONSTRATES FAVORABLE EARLY SAFETY AND EFFICACY DATA IN PATIENTS WHO HAD RECEIVED A MEDIAN FIVE PRIOR TREATMENTS.CELGENE - OVERALL RESPONSE RATE WAS 32%, WITH 29% ACHIEVING A PARTIAL RESPONSE AND TWO PATIENTS ACHIEVING A VERY GOOD PARTIAL RESPONSE.SIX PATIENTS (9%) DISCONTINUED TREATMENT DUE TO ADVERSE EVENTS.  Full Article

Bristol-Myers Squibb Co Announces Extension Of The Expiration Date For Exchange Offers For Celgene Corp Notes
Friday, 24 May 2019 

May 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB COMPANY ANNOUNCES EXTENSION OF THE EXPIRATION DATE FOR EXCHANGE OFFERS FOR CELGENE CORPORATION NOTES.BRISTOL-MYERS SQUIBB - EXTENDS EXPIRATION DATE FROM 5:00 P.M., NEW YORK CITY TIME, ON JUNE 3, 2019, TO 5:00 P.M., NEW YORK CITY TIME, ON JULY 8, 2019.BRISTOL-MYERS SQUIBB - EXTENSION OF EXPIRATION DATE OF OFFERS TO EXCHANGE NOTES ISSUED BY CELGENE FOR UP TO $19.85 BILLION OF NEW NOTES TO BE ISSUED BY CO.  Full Article

Celgene Receives European Commission Approvals For Revlimid® (Lenalidomide) And Imnovid® (Pomalidomide)-Based Triplet Combination Regimens For Patients With Multiple Myeloma
Thursday, 16 May 2019 

Celgene Corp ::CELGENE RECEIVES EUROPEAN COMMISSION APPROVALS FOR REVLIMID® (LENALIDOMIDE) AND IMNOVID® (POMALIDOMIDE)-BASED TRIPLET COMBINATION REGIMENS FOR PATIENTS WITH MULTIPLE MYELOMA.CELGENE CORP - APPROVAL FOR REVLIMID TRIPLET (RVD) WAS SUPPORTED BY DATA FROM SWOG S0777(3).CELGENE CORP - EUROPEAN COMMISSION HAS APPROVED TWO OF CELGENE'S IMID(®)-BASED COMBINATION REGIMENS.CELGENE CORP - APPROVAL OF IMNOVID TRIPLET (PVD) WAS SUPPORTED BY DATA FROM OPTIMISMM(4).CELGENE CORP - EC APPROVED TWO NEW TRIPLET REGIMENS BASED ON CELGENE'S PROPRIETARY IMID TREATMENTS, REVLIMID (LENALIDOMIDE) AND IMNOVID (POMALIDOMIDE).  Full Article

Celgene Corp Announces Pomalyst Granted Breakthrough Therapy Designation From FDA For HIV-Positive And Negative Kaposi Sarcoma
Monday, 13 May 2019 

May 13 (Reuters) - Celgene Corp ::CELGENE CORPORATION ANNOUNCES POMALYST® GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR HIV-POSITIVE AND NEGATIVE KAPOSI SARCOMA.CELGENE CORP - CELGENE PLANS TO SUBMIT SNDA BY END OF 2019.CELGENE CORP - CELGENE PLANS ADDITIONAL STUDIES WITH AIDS MALIGNANCY CONSORTIUM IN U.S. AND SUB-SAHARAN AFRICA.CELGENE CORP - POMALYST IS NOT APPROVED FOR KAPOSI SARCOMA IN ANY COUNTRY.  Full Article

Presage Announces Collaboration With Celgene To Investigate Novel Agents With Civo Technology
Thursday, 2 May 2019 

May 2 (Reuters) - Celgene Corp ::PRESAGE ANNOUNCES COLLABORATION WITH CELGENE TO INVESTIGATE NOVEL AGENTS WITH CIVO TECHNOLOGY.PRESAGE BIOSCIENCES - RESEARCH AGREEMENT TO SUPPORT PHASE 0 TUMOR MICRODOSING STUDIES.  Full Article

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb
Friday, 12 Apr 2019 

April 12 (Reuters) - Celgene Corp ::CELGENE STOCKHOLDERS APPROVE PROPOSED ACQUISITION BY BRISTOL-MYERS SQUIBB.CELGENE CORP - CELGENE EXPECTS TRANSACTION TO CLOSE IN Q3 OF 2019.CELGENE CORP - APPROXIMATELY 98% OF VOTES CAST, AND OVER 70% OF SHARES OUTSTANDING AND ENTITLED TO VOTE, VOTED IN FAVOR OF TRANSACTION.  Full Article

Dr.Reddy's Laboratories Enter Settlement Agreement With Celgene
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Celgene Corp ::DR.REDDY'S LABORATORIES- ENTERED SETTLEMENT AGREEMENT WITH CELGENE FOR ANDS RELATED TO GENERIC VERSION OF REVLIMID® BRAND CAPSULES.DR.REDDY'S LABORATORIES-CO, CELGENE AGREED TO DISCONTINUE LEGAL PROCEEDINGS INVOLVING CERTAIN OF CELGENE'S CANADIAN PATENTS RELATED TO LENALIDOMIDE.  Full Article

Bristol-Myers Says It Is Pleased Celgene Reached Settlement With Alvogen On Revlimid Patent Litigation
Friday, 29 Mar 2019 

March 29 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON CELGENE’S SETTLEMENT WITH ALVOGEN ON REVLIMID® PATENT LITIGATION.BRISTOL-MYERS SQUIBB CO - CONFIDENT IN STRENGTH OF OUR COMBINATION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - CO, CELGENE EXPECT TRANSACTION TO CLOSE IN Q3.BRISTOL-MYERS SQUIBB CO - PLEASED THAT CELGENE HAS REACHED A SETTLEMENT WITH ALVOGEN RELATED TO PATENTS FOR REVLIMID.  Full Article

Photo

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video